These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 1969855)

  • 1. The pharmacology of current anti-migraine drugs.
    Peroutka SJ
    Headache; 1990 Jan; 30(1 Suppl):5-11; discussion 24-8. PubMed ID: 1969855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Developments in 5-hydroxytryptamine receptor pharmacology in migraine.
    Peroutka SJ
    Neurol Clin; 1990 Nov; 8(4):829-39. PubMed ID: 2259314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-migraine drugs in development: advances in serotonin receptor pharmacology.
    Humphrey PP; Feniuk W; Perren MJ
    Headache; 1990 Jan; 30(1 Suppl):12-6; discussion 24-8. PubMed ID: 2157682
    [No Abstract]   [Full Text] [Related]  

  • 4. The selectivity of MDL 74,721 in models of neurogenic versus vascular components of migraine.
    Petty MA; Elands J; Johnson MP; Linnik MD; Hamel E; Moskowitz MA; Lee WS; McCarty DR; Hibert M; Baron BM
    Eur J Pharmacol; 1997 Oct; 336(2-3):127-36. PubMed ID: 9384224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Serotonin agonists and antagonists in migraine].
    Ollat H
    Pathol Biol (Paris); 1992 Apr; 40(4):389-96. PubMed ID: 1353874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 5-Hydroxtryptamine1D receptor agonism predicts antimigraine efficacy.
    Deliganis AV; Peroutka SJ
    Headache; 1991 Apr; 31(4):228-31. PubMed ID: 1646776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From serotonin receptor classification to the antimigraine drug sumatriptan.
    Saxena PR; Ferrari MD
    Cephalalgia; 1992 Aug; 12(4):187-96. PubMed ID: 1326401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SUMATRIPTAN: a receptor-targeted treatment for migraine.
    Moskowitz MA; Cutrer FM
    Annu Rev Med; 1993; 44():145-54. PubMed ID: 8386498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting to 5-HT1F receptor subtype for migraine treatment: lessons from the past, implications for the future.
    Mitsikostas DD; Tfelt-Hansen P
    Cent Nerv Syst Agents Med Chem; 2012 Dec; 12(4):241-9. PubMed ID: 22934751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of mRNA for the serotonin 5-hydroxytryptamine1D beta receptor subtype in human and bovine cerebral arteries.
    Hamel E; Fan E; Linville D; Ting V; Villemure JG; Chia LS
    Mol Pharmacol; 1993 Aug; 44(2):242-6. PubMed ID: 8394988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical effects and mechanism of action of sumatriptan in migraine.
    Ferrari MD; Saxena PR
    Clin Neurol Neurosurg; 1992; 94 Suppl():S73-7. PubMed ID: 1320526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5-Hydroxytryptamine receptor subtypes and the pharmacology of migraine.
    Peroutka SJ
    Neurology; 1993 Jun; 43(6 Suppl 3):S34-8. PubMed ID: 8389009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of avitriptan, a new 5-HT 1B/1D receptor agonist, in experimental models predictive of antimigraine activity and coronary side-effect potential.
    Saxena PR; De Vries P; Wang W; Heiligers JP; Maassen vandenBrink A; Bax WA; Yocca FD
    Naunyn Schmiedebergs Arch Pharmacol; 1997 Feb; 355(2):295-302. PubMed ID: 9050026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serotonin receptor subtypes and neuropsychiatric diseases: focus on 5-HT1D and 5-HT3 receptor agents.
    Peroutka SJ
    Pharmacol Rev; 1991 Dec; 43(4):579-86. PubMed ID: 1663621
    [No Abstract]   [Full Text] [Related]  

  • 15. Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamine and [3H]alniditan.
    Leysen JE; Gommeren W; Heylen L; Luyten WH; Van de Weyer I; Vanhoenacker P; Haegeman G; Schotte A; Van Gompel P; Wouters R; Lesage AS
    Mol Pharmacol; 1996 Dec; 50(6):1567-80. PubMed ID: 8967979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Agonist activity of sumatriptan and metergoline at the human 5-HT1D beta receptor: further evidence for a role of the 5-HT1D receptor in the action of sumatriptan.
    Miller KJ; King A; Demchyshyn L; Niznik H; Teitler M
    Eur J Pharmacol; 1992 Sep; 227(1):99-102. PubMed ID: 1330643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Further characterization of the putative 5-HT receptor which mediates blockade of neurogenic plasma extravasation in rat dura mater.
    Buzzi MG; Moskowitz MA; Peroutka SJ; Byun B
    Br J Pharmacol; 1991 Jun; 103(2):1421-8. PubMed ID: 1653072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical studies on the anti-migraine drug, sumatriptan.
    Humphrey PP; Feniuk W; Marriott AS; Tanner RJ; Jackson MR; Tucker ML
    Eur Neurol; 1991; 31(5):282-90. PubMed ID: 1653134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sumatriptan is a potent vasoconstrictor of human dural arteries via a 5-HT1-like receptor.
    Jansen I; Edvinsson L; Mortensen A; Olesen J
    Cephalalgia; 1992 Aug; 12(4):202-5. PubMed ID: 1326402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Wolff Award presentation 1993. Anti-migraine drug interactions with cloned human 5-hydroxytryptamine1 receptor subtypes.
    Peroutka SJ; Havlik S; Oksenberg D
    Headache; 1993; 33(7):347-50. PubMed ID: 8397171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.